Tracked deals
6
6 tracked deals across 2019-2026.
Operating Company
Healthcare
Azurity Pharmaceuticals
Woburn, Massachusetts, United States
Azurity Pharmaceuticals is a specialty pharmaceutical company with a global footprint focused on developing, commercializing, and delivering medicines across multiple therapeutic areas for overlooked patients. The company operates an enterprise model to rethink how therapies are designed, delivered, and accessed.
- Focus Areas
- Specialty pharmaceuticals, Overlooked-patient dose-form medicines, Complex dosage forms
- Website
- azurity.com
Recent pace
2
2 tracked deals announced in the last 12 months.
Deal mix
Buyout
3 buyout · 2 addon · 1 divestiture
Azurity Pharmaceuticals Acquisition Volume by Year
Last 5 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
July 17, 2026
- Buyer
- GH Power Inc., Azurity Pharmaceuticals, Inc., GH Power International (newly formed public parent)
- Target
- Matinas BioPharma Holdings, Inc., Matinas BioPharma Nanotechnologies, Inc.
- Industry
- Energy
- Location
- United States
- Type
- Buyout
GH Power Inc. entered into a definitive business combination agreement with Matinas BioPharma Holdings, Inc. to create a NYSE-listed, publicly traded critical minerals and clean energy company. A newly formed Ontario parent (“GH Power International”) would become the public parent of both companies, with the deal expected to close in Q4 2026 subject to customary approvals. Separately, Matinas also signed a definitive stock purchase agreement with Azurity Pharmaceuticals, Inc. under which Azurity will acquire Matinas BioPharma Nanotechnologies, Inc. (including the lipid nano-crystal (LNC) platform technology and lead candidate MAT2203) for $4 million upfront plus up to $17.5 million in milestones and royalties.
-
November 17, 2025
- Buyer
- Azurity Pharmaceuticals
- Target
- Sebela Pharmaceuticals' Bowel Prep Franchise
- Seller
- Sebela Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Azurity Pharmaceuticals has acquired Sebela Pharmaceuticals' bowel preparation franchise, including two leading bowel prep therapies used for colonoscopies. The deal transfers Sebela's commercial team (more than 50 colleagues) and is intended to strengthen Azurity's gastroenterology product portfolio and U.S. market presence.
-
March 14, 2025
- Buyer
- Azurity Pharmaceuticals
- Target
- Covis Group S.à r.l. (Covis Pharma)
- Seller
- Existing investors
- Industry
- Pharmaceuticals
- Location
- Switzerland
- Type
- Buyout
Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.
-
September 27, 2023
- Buyer
- Azurity Pharmaceuticals, Inc.
- Target
- Slayback Pharma LLC
- Seller
- KKR, Everstone Capital
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.
-
September 24, 2021
- Buyer
- Azurity Pharmaceuticals, Inc., NovaQuest Private Equity
- Target
- Arbor Pharmaceuticals, Inc.
- Seller
- JW Asset Management, KKR
- Industry
- Pharmaceuticals
- Location
- Georgia, United States
- Type
- Addon
Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.
-
June 12, 2019
- Buyer
- CutisPharma, Inc., NovaQuest Private Equity (QHP Capital)
- Target
- Silvergate Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Colorado, United States
- Type
- Buyout
CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
5 tracked deals by Azurity Pharmaceuticals.
Energy Buyers & Acquisitions
1 tracked deal by Azurity Pharmaceuticals.
Acquisitions in Colorado
1 tracked deal by Azurity Pharmaceuticals.
Acquisitions in Georgia
1 tracked deal by Azurity Pharmaceuticals.
Acquisitions in Massachusetts
1 tracked deal by Azurity Pharmaceuticals.
Acquisitions in New Jersey
1 tracked deal by Azurity Pharmaceuticals.
Selling a company? Get in front of buyers like Azurity Pharmaceuticals
Turn tracked acquisition activity into an outreach-ready buyer list.